You have access
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study
LUÍS MANSO, ANDRÉS GARCÍA PALOMO, RAMÓN PÉREZ CARRIÓN, JAVIER CASSINELLO, ISABEL GALLEGOS SANCHO, IGNACIO CHACÓN LÓPEZ-MUÑIZ, CLARA OLIER, ANTONIO FERNÁNDEZ-ARAMBURO, CRISTINA LLORCA, XAVIER GONZÁLEZ, ROSA LLORENTE, DOLORES TORREGROSA, IÑAKI ÁLVAREZ, ELENA GÁLVE, CORALIA BUENO, ISABEL GARAU, MARÍA JOSÉ GARCÍA, SANTIAGO GONZÁLEZ-SANTIAGO, ANA ISABEL BALLESTEROS, ESPERANZA BLANCO, ANTONIO GALÁN, SONIA GONZÁLEZ, ANTONIA PERELLÓ, HERNÁN CORTÉS-FUNES and CRISTINA GRÁVALOS
Anticancer Research December 2015, 35 (12) 6941-6950;